Cabio Biotech (Wuhan) Co., Ltd. (688089.SS) SHH
Currency In CNY
- General
- Statistics
- Historical Data
- Profile
- Financials
Cabio Biotech (Wuhan) Co., Ltd.
Sector
Healthcare
Industry
Biotechnology
Employees
565
First IPO Date
December 19, 2019
Key Executives
| Name | Title | Pay | Year Born |
| Zhi Bo Li | Deputy General Manager | 0 | 1973 |
| Dewei Yi | Chairman & GM | 0 | 1965 |
| Huabiao Wang | Financial Director & Director | 0 | 1965 |
| Huarong Yi | Deputy GM & Secretary of the Board of Directors | 0 | 1976 |
| Hao Xiong | Accounting Supervisor | 0 | N/A |
| Xiangyu Li | Deputy General Manager | 0 | 1978 |
| Anfeng Geng | Deputy General Manager | 0 | 1976 |
Description
Cabio Biotech (Wuhan) Co., Ltd. focuses on the development, production, and worldwide distribution of crucial nutritional compounds such as arachidonic acid (ARA), docosahexaenoic acid (DHA), and beta-carotene. These ingredients are primarily supplied to manufacturers, both within China and internationally, who specialize in infant formula and healthy food products. The company's versatile offerings are incorporated into a wide array of goods, including infant nutritionals, health foods, dietary supplements, specialized medical purpose foods, pet food, commercial animal feed, and even personal care and cosmetic items. Founded in 1999, the company is headquartered in Wuhan, located in the People's Republic of China.